Larotrectinib

What is Larotrectinib?

Larotrectinib is an innovative oral targeted therapy for specific cancers. It treats tumors harboring NTRK gene fusions (neurotrophic tyrosine receptor kinase gene fusions), rare genetic alterations found across various solid tumors. Larotrectinib inhibits overactive TRK proteins resulting from these fusions, blocking signals that drive cancer cell growth. Marketed as Vitrakvi, it offers a crucial treatment option based on a tumor's specific genetic signature, marking a significant advancement in precision oncology.

How Does it Work?

Larotrectinib specifically targets the tropomyosin receptor kinase (TRK) proteins (TRKA, TRKB, TRKC). In certain cancers, NTRK gene fusions create abnormal, hyperactive TRK fusion proteins, which act as oncogenic drivers, signaling uncontrolled cell growth. Larotrectinib is a potent and selective inhibitor of these fusion proteins. By binding to their kinase domain, it blocks downstream signaling pathways that promote proliferation and survival. This targeted action primarily affects cancer cells with the NTRK gene fusion, largely sparing healthy cells, leading to a more favorable side effect profile. Its ability to cross the blood-brain barrier also suggests potential activity against CNS metastases.

Medical Uses

Larotrectinib is indicated for adult and pediatric patients with solid tumors harboring an NTRK gene fusion. Key criteria include:

• The cancer is locally advanced or metastatic, or surgical resection would cause severe morbidity.
• No satisfactory alternative treatments available.
• The tumor has been confirmed to harbor an NTRK gene fusion via a validated diagnostic test.

This makes Larotrectinib a tumor-agnostic therapy, applicable to various cancer types (e.g., lung, thyroid, sarcoma) possessing this specific genetic fusion. Clinical trials have demonstrated significant and durable responses across a wide range of tumors, highlighting its broad applicability for this genetically defined subset of cancers.

Dosage

Larotrectinib (Vitrakvi) dosage varies by age and body surface area (BSA) for pediatric patients.

• Adults: 100 mg orally twice daily, approximately 12 hours apart, with or without food.
• Pediatric Patients:
  • BSA ≥ 1.0 m²: 100 mg twice daily.
  • BSA < 1.0 m²: 100 mg/m² twice daily, max 100 mg per dose.

Available as capsules (25 mg, 100 mg) and oral solution (20 mg/mL). Dosing adjustments may be needed based on tolerance and adverse reactions. Patients must follow healthcare provider instructions precisely and not adjust doses without consultation.

Side Effects

While generally well-tolerated, Larotrectinib can cause side effects. Common reactions include:

• Fatigue, nausea, vomiting, diarrhea, constipation.
• Dizziness, anemia, increased liver enzymes, increased creatinine, weight gain.

More serious, though less common, side effects:

• Neurological effects: Dizziness, ataxia, paresthesia, tremor. Usually mild to moderate, requiring monitoring.
• Hepatotoxicity: Liver enzyme elevations, potentially requiring dose modification.
• QT interval prolongation: Rare but serious, requiring caution in patients with pre-existing cardiac conditions.

Patients should report any new or worsening symptoms to their healthcare provider promptly.

Drug Interactions

Larotrectinib is primarily metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors or inducers can significantly alter its plasma concentrations.

• Strong CYP3A4 Inhibitors: (e.g., ketoconazole, clarithromycin, grapefruit juice) can increase Larotrectinib exposure, potentially increasing toxicity. Dose reduction may be necessary.
• Strong CYP3A4 Inducers: (e.g., rifampin, phenytoin, St. John's wort) can decrease Larotrectinib exposure, potentially reducing efficacy. Dose increase may be necessary.
• CYP3A4 Substrates: Larotrectinib is a moderate CYP3A4 inhibitor, increasing concentrations of other drugs metabolized by CYP3A4 (e.g., midazolam, simvastatin). Concomitant use with narrow therapeutic index CYP3A4 substrates requires caution.

Patients should inform their doctor and pharmacist about all medications and supplements.

FAQ

What is an NTRK gene fusion?

It's a genetic alteration where part of an NTRK gene fuses with another, creating an overactive TRK protein that drives cancer. This fusion is the target for therapies like Larotrectinib.

Is Larotrectinib chemotherapy?

No, Larotrectinib is a targeted therapy. It specifically inhibits TRK fusion proteins in cancer cells, unlike chemotherapy, which broadly attacks rapidly dividing cells.

How is an NTRK gene fusion detected?

Through molecular diagnostic tests on tumor tissue or blood, using methods like next-generation sequencing (NGS), FISH, or IHC. Your doctor will advise on testing.

Can Larotrectinib cure cancer?

While effective in shrinking tumors and prolonging survival, Larotrectinib is generally considered a treatment to control the disease, not a cure. Research continues.

Who is eligible for Larotrectinib treatment?

Eligibility requires a solid tumor with an NTRK gene fusion, advanced or metastatic cancer (or high surgical morbidity), and no other satisfactory treatment options. Genetic testing confirms this.

Products containing Larotrectinib are available through trusted online pharmacies. You can browse Larotrectinib-based medications at ShipperVIP or Medicenter.

Summary

Larotrectinib is a significant oncology breakthrough, offering highly effective, precisely targeted treatment for patients with TRK fusion cancer. By inhibiting abnormal TRK fusion proteins, it halts cancer cell growth across diverse solid tumors. This tumor-agnostic approach, delivered as Vitrakvi, exemplifies genomic-driven cancer care. While generally well-tolerated, understanding potential side effects and drug interactions is crucial. Larotrectinib provides hope for patients with this specific genetic alteration, improving outcomes through precision medicine.